CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 216 target
Drug / intervention
DR30206drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06132828
NCT06132828Phase 1RecruitingOn TrackUpdated 2mo ago
CompareCT.gov

A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Zhejiang Doer Biologics Co., Ltd.·interventional·Posted Nov 15, 2023·Updated Apr 27, 2026

In Brief

A Phase 1 clinical trial evaluating DR30206 for Solid Tumor. Currently recruiting, targeting 216 participants across 1 site.

Detailed Summary

This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
2024202520262027
First PostedNov 15, 2023
Enrollment StartNov 27, 2023
Primary CompletionJul 30, 2027
Study CompletionSep 30, 2027
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 2.6 years agoPrimary completion in 1.1 years

Interventions

DR30206drug

Subjects receive DR30206 intravenously